|
Ciltacabtagene Autoleucel Clinical Trials
4 actively recruiting trials across 3 locations
Also known as: Autologous Anti-B-cell maturation antigen (BCMA) CAR-T Cells JNJ-68284528, Autologous Anti-BCMA CAR-T Cells JNJ-68284528, Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528, Autologous Bi-epitope CAR T-cells JNJ-68284528, CARVYKTI +10 more
Pipeline
Phase 1: 2Phase 2: 1
Top Sponsors
- Washington University School of Medicine1
- St. Olavs Hospital1
- Medical College of Wisconsin1
- Mayo Clinic1
Indications
- Cancer4
- Refractory Multiple Myeloma2
- Recurrent Multiple Myeloma1
- Relapse Multiple Myeloma1
- Myeloma, Multiple1
Other1 trial
Rochester, Minnesota1 trial
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic in Rochester
Phase 2
St Louis, Missouri1 trial
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Washington University School of Medicine
Phase 1
Milwaukee, Wisconsin1 trial
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Froedtert & the Medical College of Wisconsin
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.